

15. Legrand O, Simonin G, Perrot J-Y, et al. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. *Blood*. 1998;91:4480–4488.
16. Goldenberg DM. Target therapy of cancer with radiolabeled antibodies. *J Nucl Med*. 2002;43:693–713.
17. Burke JM, Jurcic JG. Radioimmunotherapy of leukemia. *Adv Pharmacol*. 2004;51:185–208.
18. Todd WM. Acute myeloid leukemia and related conditions. *Hematol Oncol Clin North Am*. 2002;16:301–319.
19. Andrews RG, Torok-Storb B, Bernstein ID. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. *Blood*. 1983;62:124–132.
20. Griffin JD, Linch D, Sabbath K, et al. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. *Leuk Res*. 1984;8:521–534.
21. Mattes MJ. Radionuclide-antibody conjugates for single-cell cytotoxicity. *Cancer*. 2002;94(4 suppl):1215–1223.
22. Burke JM, Jurcic JG, Scheinberg DA. Radioimmunotherapy for acute leukemia. *Cancer Control*. 2002;9:106–113.
23. Michel RB, Andrews PM, Castillo ME, Mattes MJ. In vitro cytotoxicity of carcinoma cells with ¹¹¹In-labeled antibodies to HER-2. *Mol Cancer Ther*. 2005;4:927–937.
24. Buchegger F, Perillo-Adamer F, Dupertuis YM, Delaloye AB. Auger radiation target into DNA: a therapy perspective. *Eur J Nucl Med Mol Imaging*. 2006;33:1352–1363.
25. van der Holt B, Lowenberg B, Burnett AK, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR status at diagnosis. *Blood*. 2005;106:2646–2654.
26. Solary E, Drenou B, Campos L, et al. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. *Blood*. 2003;102:1202–1210.
27. Tanimoto M, Scheinberg DA, Cordon-Cardo C, et al. Restricted expression of an early myeloid and monocytic cell surface. *Leukemia*. 1989;3:339–348.
28. Miederer M, McDevitt MR, Sgouros G, et al. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, ²²⁵Ac-HuM195, in nonhuman primates. *J Nucl Med*. 2004;45:129–137.

Erratum

In the article “SPECT/CT,” by Buck et al. (*J Nucl Med*. 2008;49:1305–1319), the legends of Figures 1, 5, and 6 contain errors. In the legend of Figure 1, “^{99m}Tc-iodobenzamide” should be “¹²³I-ioflupane (DaTSCAN [GE Healthcare]).” In the legend of Figure 5, panel B is described as a ^{99m}Tc-MIBI scan but is in fact a ^{99m}Tc-pertechnetate scan. In the legend of Figure 6, “^{99m}Tc-MIBG” should be “¹²³I-MIBG.” The authors regret the errors.